Transaction DateRecipientSharesTypePriceValue
8th February 2021Jeffrey F Odonnell42,762Open or private sale$5.12$219,099.66
5th February 2021Jeffrey F Odonnell62,238Open or private sale$5.00$311,270.91
6th January 2021Jerome B Zeldis1,650Grant/award etc.$0.00
4th January 2021Steve Chaussy150,000Grant/award etc.$0.00
4th January 2021Kenneth L Londoner300,000Grant/award etc.$0.00
1st December 2020Steve Chaussy2,000Open or private purchase$4.35$8,699.00
30th November 2020Kenneth L Londoner2,000Open or private purchase$4.65$9,300.00
24th November 2020Kenneth L Londoner1,000Open or private purchase$4.33$4,330.00
23rd November 2020Kenneth L Londoner1,000Open or private purchase$4.51$4,510.00
23rd November 2020Kenneth L Londoner1,000Open or private purchase$4.39$4,390.00
Bio Sig Technologies
Bio Sig Technologies logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


BioSig Technologies, Inc. is a medical technology company developing a biomedical signal processing platform. The company is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.


Ticker: BSGM
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1530766
Employees: 33
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $37 M (0%)
Inventory, Net: $800 Th (0%)
Assets, Current: $39 M (201%)
Property, Plant and Equipment, Net: $175 Th (0%)
Assets: $40 M (180%)
Liabilities, Current: $4 M (77%)
Common Stock, Value, Issued: $29 Th (24%)
Common Stock, Shares, Issued: $29 M (24%)
Retained Earnings (Accumulated Deficit): $135 M (29%)
Stockholders' Equity (Parent): $33 M (198%)
Liabilities and Equity: $40 M (180%)
Research and Development: $6 M (0%)
General and Administrative Expenses: $17 M (0%)
Operating Income/Loss: $22 M (-36%)
Income before taxes: $22 M (-36%)